Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 78, Issue 3, Pages S37-S42Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2017.12.018
Keywords
atopic dermatitis; dipeptidyl peptidase-4; Eczema Area and Severity Index; interleukin; IL-31RA; Investigator's Global Assessment; Janus kinase; c-Jun N-terminal kinase; mitogen-activated protein kinase; oncostatin M receptor beta; STAT signal transducer and activator of transcription; T helper; topical corticosteroids; Visual Analogue Scale.
Categories
Funding
- Bayer [19670]
- LEO Pharma
- Sanofi Genzyme [IME-2017-11043]
- Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish
Ask authors/readers for more resources
The interleukin 13 (IL-13) and IL-31 cytokines and inflammatory pathways have been identified as important for the pathophysiology of atopic dermatitis (AD). Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, 2 phase 2 trials have been completed with these antibodies in AD treatment. In both trials, significant reductions of Eczema Area and Severity Index scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in patients with AD. One phase 2 trial has been completed for a humanized antibody against IL-31 receptor alpha, which is 1 subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, Eczema Area and Severity Index scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long-term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe AD. (J Am Acad Dermatol 2018; 78: S37-42.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available